Kronos Bio Inc. (KRON)
NASDAQ (CM) NASDAQ (CM) Primary 
Kronos Bio downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Edward Tenthoff downgraded Kronos Bio to Neutral from Overweight with a price target of $1, down from $6.
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.54 per share a year ago.
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
The heavy selling pressure might have exhausted for Kronos Bio (KRON) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?
Kronos Bio (KRON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround
Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
